CN111920799B - 一种苦乐果有效成分组合物及其制备方法和应用 - Google Patents
一种苦乐果有效成分组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN111920799B CN111920799B CN202010816803.XA CN202010816803A CN111920799B CN 111920799 B CN111920799 B CN 111920799B CN 202010816803 A CN202010816803 A CN 202010816803A CN 111920799 B CN111920799 B CN 111920799B
- Authority
- CN
- China
- Prior art keywords
- component
- kule
- drying
- fruit
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 238000001035 drying Methods 0.000 claims abstract description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- PFHZIWAVXDSFTB-UHFFFAOYSA-N hibiscusoic acid Natural products OC(=O)C1OC(=O)CC1(O)C(O)=O PFHZIWAVXDSFTB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000007791 liquid phase Substances 0.000 claims abstract description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 84
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- 239000000843 powder Substances 0.000 claims description 45
- 239000000284 extract Substances 0.000 claims description 39
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 19
- QOFWRHWADNWKSU-LRXIOGKNSA-N (2e,6e,10e)-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydrochromen-2-yl]-2,6,10-trimethyltrideca-2,6,10-trienoic acid Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC\C=C(CC\C=C(/C)C(O)=O)/C)(C)CCC2=C1 QOFWRHWADNWKSU-LRXIOGKNSA-N 0.000 claims description 17
- 238000002137 ultrasound extraction Methods 0.000 claims description 14
- QOFWRHWADNWKSU-UHFFFAOYSA-N (11'E)-delta-Tocotrienol acid Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(CCC=C(C)C(O)=O)C)(C)CCC2=C1 QOFWRHWADNWKSU-UHFFFAOYSA-N 0.000 claims description 12
- 238000010828 elution Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 238000002386 leaching Methods 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000012071 phase Substances 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 9
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 65
- 239000008280 blood Substances 0.000 abstract description 65
- 230000001603 reducing effect Effects 0.000 abstract description 40
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 11
- 201000001421 hyperglycemia Diseases 0.000 abstract description 10
- 230000002195 synergetic effect Effects 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 240000001592 Amaranthus caudatus Species 0.000 abstract description 2
- 235000009328 Amaranthus caudatus Nutrition 0.000 abstract description 2
- 230000009471 action Effects 0.000 abstract description 2
- 235000012735 amaranth Nutrition 0.000 abstract description 2
- 239000004178 amaranth Substances 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 17
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 239000007788 liquid Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- GJWXCPDVDRIBKP-CNTBMXMRSA-N kolaflavanone Chemical compound C1=C(O)C(OC)=CC=C1[C@@H]1[C@@H](O)C(=O)C2=C(O)C=C(O)C([C@H]3C(C4=C(O)C=C(O)C=C4O[C@@H]3C=3C=CC(O)=CC=3)=O)=C2O1 GJWXCPDVDRIBKP-CNTBMXMRSA-N 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 241001207073 Garcinia kola Species 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- UFJORDZSBNSRQT-UHFFFAOYSA-N 3-(4-oxo-2-phenylchromen-3-yl)-2-phenylchromen-4-one Chemical class O1C2=CC=CC=C2C(=O)C(C=2C(C3=CC=CC=C3OC=2C=2C=CC=CC=2)=O)=C1C1=CC=CC=C1 UFJORDZSBNSRQT-UHFFFAOYSA-N 0.000 description 3
- 235000010205 Cola acuminata Nutrition 0.000 description 3
- 244000228088 Cola acuminata Species 0.000 description 3
- 235000015438 Cola nitida Nutrition 0.000 description 3
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 230000003516 hyperlipidaemic effect Effects 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000246044 Sophora flavescens Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000489 anti-atherogenic effect Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000000260 hypercholesteremic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MXEIKUWMKSYEII-UHFFFAOYSA-N (+)-GB-1b Natural products C1=CC(O)=CC=C1C1OC2=C(C3C(C4=C(O)C=C(O)C=C4OC3C=3C=CC(O)=CC=3)=O)C(O)=CC(O)=C2C(=O)C1 MXEIKUWMKSYEII-UHFFFAOYSA-N 0.000 description 1
- MXEIKUWMKSYEII-DETITRACSA-N (2s)-8-[(2s,3r)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-2,3-dihydrochromen-3-yl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=C([C@H]3C(C4=C(O)C=C(O)C=C4O[C@@H]3C=3C=CC(O)=CC=3)=O)C(O)=CC(O)=C2C(=O)C1 MXEIKUWMKSYEII-DETITRACSA-N 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229930195164 Biflavanone Natural products 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000598860 Garcinia hanburyi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- -1 biflavone compound Chemical class 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229940117709 gamboge Drugs 0.000 description 1
- 108700004049 glycosylated serum Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010816803.XA CN111920799B (zh) | 2020-08-14 | 2020-08-14 | 一种苦乐果有效成分组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010816803.XA CN111920799B (zh) | 2020-08-14 | 2020-08-14 | 一种苦乐果有效成分组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111920799A CN111920799A (zh) | 2020-11-13 |
CN111920799B true CN111920799B (zh) | 2023-05-12 |
Family
ID=73310349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010816803.XA Active CN111920799B (zh) | 2020-08-14 | 2020-08-14 | 一种苦乐果有效成分组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111920799B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114306413A (zh) * | 2022-01-14 | 2022-04-12 | 苏州隽德生物科技有限公司 | 一种苦乐果湿疹膏的制备方法及设备 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180128781A (ko) * | 2017-05-24 | 2018-12-04 | 주식회사 씨티씨바이오 | 콜라비론의 제조방법 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2998173B1 (fr) * | 2012-11-21 | 2015-05-01 | Univ Angers | Extrait de garcinia kola, utilisation pour son action anti-glycation |
-
2020
- 2020-08-14 CN CN202010816803.XA patent/CN111920799B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180128781A (ko) * | 2017-05-24 | 2018-12-04 | 주식회사 씨티씨바이오 | 콜라비론의 제조방법 |
Non-Patent Citations (4)
Title |
---|
Anti-diabetic Profile of Extract, Kolaviron, Biflavonoids and Garcinoic acid from Garcinia kola seeds;M.K. Tchimene等;《Int.J.Curr.Microbiol.App.Sci》;20160210;第5卷(第2期);第1页右栏、第2页左栏第1段、第318页右栏第1-3段 * |
Garcinia kola seed ameliorates renal, hepatic, and testicular oxidative damage in streptozotocin-induced diabetic rats;Isaac A. Adedara等;《Pharm Biol》;20140922;第1-10页 * |
Hypoglycemic and Hypolipidemic Effect of Bitter Kola (Garcinia kola) Seed Extract on Alloxan-Induced Diabetic Albino Rats;Ibanga I. Etim等;《Journal of Biosciences and Medicines》;20200610;第8卷;第127-134页 * |
Study on characteristics of biflavanones distribution in Garcinia kola seeds and identification of compounds in gum resin exuded fromfresh slices;Xinhui Wang等;《Journal of Pharmaceutical and Biomedical Analysis》;20200802;第190卷;第1页摘要、右栏、第2页左栏第1段、右栏第2.3-2.4节、第13页图A.1,第16页图A.4 * |
Also Published As
Publication number | Publication date |
---|---|
CN111920799A (zh) | 2020-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7811997B2 (en) | Composition containing total triterpenoid sapogenins extracted from bamboo, and the preparation method and use thereof | |
CN1669573A (zh) | 一种治疗心脑血管疾病的中药制剂及其制备方法 | |
CN1754541A (zh) | 甾体皂苷药物组合物及其制备方法和用途 | |
US7078063B2 (en) | Water soluble extract from plant of Solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract | |
CN102006869B (zh) | 能量利用疾病的治疗 | |
KR101928767B1 (ko) | 돌외로부터 분리된 신규한 지페노사이드 화합물 | |
CN106220701B (zh) | 三萜化合物及其制备方法与应用 | |
CN111920799B (zh) | 一种苦乐果有效成分组合物及其制备方法和应用 | |
US20080199517A1 (en) | Composition and a process thereof | |
CN112791137B (zh) | 三种五味子提取物及其制备工艺和应用 | |
NZ573614A (en) | Processes for making caralluma extracts and uses | |
CN1814170A (zh) | 一种治疗心血管疾病的药物滴丸及其制备方法 | |
CN1861104A (zh) | 可用于治疗糖尿病和高脂血症的旋复花提取物 | |
CN1565473A (zh) | 茄属植物的水溶性萃取物、其制备方法及其药学组合物 | |
CN107837301B (zh) | 一种大叶蒟提取物及其制备方法与应用 | |
CN105796560A (zh) | 环丙沙星的药物组合物及其在生物医药中的应用 | |
CN1989984A (zh) | 川芎有效组分、制备方法及其制剂与用途 | |
Ameer et al. | Vasorelaxant properties of Loranthus ferrugineus Roxb. methanolic extract | |
TWI438001B (zh) | 用於治療糖尿病之植物萃取物及其製備方法 | |
CN107513092B (zh) | 一种丙二酰基人参皂苷Rb1的制备方法及其医用用途 | |
CN110624006A (zh) | 一种含有曲札有效成分的保健酒 | |
Silitonga | Hypoglycemic activity of extract leaf and root plant of jombang (Taraxacum Officinale) in alloxan-induced diabetic wistar male rats | |
CN115429790B (zh) | 异黄酮类化合物在制备预防或治疗酒精性肝损伤或解酒保肝的药物中的用途 | |
CN1605357A (zh) | 胡芦巴提取物及其制备方法和应用 | |
WO2009135353A1 (zh) | 梅树提取物的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240613 Address after: Unit E667, 5th Floor, Lecheng Plaza, Phase II, No. 218 Sangtian Street, Suzhou Industrial Park, Suzhou Area, Suzhou Free Trade Zone, Jiangsu Province, 215000 Patentee after: Suzhou Junde Biotechnology Co.,Ltd. Country or region after: China Address before: No. 1, Unit 1, 47th Floor, Jun'an Jingyuan, South Side of Qingnan Road, High tech Zone, Tangshan City, Hebei Province, 063000 Patentee before: Tangshan kelifuti Biotechnology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |